Ottimo Pharma
Ottimo Pharma is a pioneering biotech company focused on developing first-in-class, bi-functional antibodies for cancer treatment. Their mission is to extend the lives of people living with cancer by advancing innovative therapies that target multiple pathways, such as PD1 and VEGFR2, to improve treatment outcomes and reduce healthcare burdens. With a world-class leadership team and significant backing from top investors, Ottimo aims to bring novel cancer therapies into clinical development, with plans to file an IND in late 2025.
Industries
Nr. of Employees
small (1-50)
Ottimo Pharma
Ottimo Pharma, [Address not specified in the content]
Patents
Products
Lead PD1/VEGFR2 bifunctional antibody program
A first-in-class bifunctional, biparatopic IgG therapeutic designed to concurrently inhibit PD1-mediated immune checkpoint pathways and modulate VEGFR2-mediated angiogenesis, developed for multiple solid tumor indications.
Pipeline of follow-on bifunctional antibody assets
Additional bifunctional antibody programs in preclinical development intended to expand therapeutic approaches targeting multiple pathways in oncology.
Lead PD1/VEGFR2 bifunctional antibody program
A first-in-class bifunctional, biparatopic IgG therapeutic designed to concurrently inhibit PD1-mediated immune checkpoint pathways and modulate VEGFR2-mediated angiogenesis, developed for multiple solid tumor indications.
Pipeline of follow-on bifunctional antibody assets
Additional bifunctional antibody programs in preclinical development intended to expand therapeutic approaches targeting multiple pathways in oncology.
Expertise Areas
- Antibody discovery and engineering
- Preclinical and translational research in immuno-oncology
- Biologics CMC and formulation development
- Manufacturing process development and scale-up for biologics
Key Technologies
- Bifunctional/biparatopic antibody modalities
- Therapeutic IgG biologics
- Antibody engineering and optimization
- Intravenous and subcutaneous biologic formulations
News & Updates
Ottimo Pharma announces the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.
Ottimo Pharma announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development.
Ottimo Pharma completes a Series A financing round of over $140 million to accelerate development of its lead asset, Jankistomig, a PD1/VEGFR2 bifunctional antibody.
Ottimo Pharma, co-founded by Medicxi and Jonny Finlay, announced its emergence from stealth with backing from top investors and leadership to develop a novel PD1/VEGFR2 bi-functional antibody.
Ottimo Pharma announced the completion of a Series A financing round of over $140 million, led by top healthcare investors, to support its pipeline of bifunctional cancer therapies.
Ottimo Pharma, a private biotech company, announced its emergence from stealth with backing from Medicxi and a leadership team to develop a PD1-VEGFR2 bi-functional antibody.
Ottimo Pharma announces the appointment of Roger Dansey, M.D., a prominent leader in oncology research and drug development, to its board of directors.
Ottimo Pharma announces the appointment of Robert Tighe as Senior Vice President of Preclinical and Translational Sciences, and Katherine Bell-McGuinn as Senior Vice President of Clinical Development.
Ottimo Pharma completes a Series A financing round of over $140 million to accelerate development of its lead asset, Jankistomig, a PD1/VEGFR2 bifunctional antibody.
Ottimo Pharma, co-founded by Medicxi and Jonny Finlay, announced its emergence from stealth with backing from top investors and leadership to develop a novel PD1/VEGFR2 bi-functional antibody.
Ottimo Pharma announced the completion of a Series A financing round of over $140 million, led by top healthcare investors, to support its pipeline of bifunctional cancer therapies.
Ottimo Pharma, a private biotech company, announced its emergence from stealth with backing from Medicxi and a leadership team to develop a PD1-VEGFR2 bi-functional antibody.